A great many forces are in play in the global market to address the single condition with the most pervasive implications — obesity. Its increasing prevalence in western markets, coupled a serious list of co-morbidities, while treatment options, however numerous, are still less than robust especially for drug options, and while emerging markets and their patients are increasingly resembling western markets with an abundance of appreciation for high caloric diets and sedentary lifestyles, are all leading to changes in the size and shape of the market for obesity treatments and their attractiveness as medtech opportunities.
One of the more telling graphics we have previously presented in the area of obesity treatment options, is the comparison of European versus Asia/Pacific markets from 2011 to 2019 (below). While the vertical scale of the market changes significantly from 2011 to 2019 to reflect the roughly three-fold growth of the market, the most interesting change is the reversal of the relative size of the market for European versus Asia/Pacific markets, reflecting the rather unfortunate, “westernization” of Asia/Pacific.
Source: MedMarket DIligence, LLC; Report #S835, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019.”